Carnitine Palmitoyltransferase II Deficiency (CPT II) Followed By Rhabdomyolysis and Acute Kidney Injury

Authors

  • Nikola Gjorgjievski University Clinic of Nephrology Skopje, Ss Cyril and Methodius University of Skopje, Skopje
  • Pavlina Dzekova-Vidimliski University Clinic of Nephrology Skopje, Ss Cyril and Methodius University of Skopje, Skopje
  • Zvezdana Petronijevic University Clinic of Nephrology Skopje, Ss Cyril and Methodius University of Skopje, Skopje
  • Gjulsen Selim University Clinic of Nephrology Skopje, Ss Cyril and Methodius University of Skopje, Skopje
  • Petar Dejanov University Clinic of Nephrology Skopje, Ss Cyril and Methodius University of Skopje, Skopje
  • Liljana Tozija University Clinic of Nephrology Skopje, Ss Cyril and Methodius University of Skopje, Skopje
  • Aleksandar Sikole University Clinic of Nephrology Skopje, Ss Cyril and Methodius University of Skopje, Skopje

DOI:

https://doi.org/10.3889/oamjms.2018.158

Keywords:

Carnitine palmitoyltransferase II deficiency, Rhabdomyolysis, Metabolic disorder, Creatine kinase, Myoglobin, Acute kidney injury, Hemodialysis

Abstract

BACKGROUND: Carnitine palmitoyltransferase II deficiency (CPT II) is an autosomal recessive disorder and the most common inherited disorder of mitochondrial long-chain fatty acid oxidation, characterised by attacks of myalgia and myoglobinuria. The most common “classic†myopathic form occurs in young adults and is characterised by recurrent episodes of rhabdomyolysis triggered by prolonged exercise, fasting or febrile illness.

CASE PRESENTATION: We present a case of a 22-year-old Caucasian male admitted to our hospital with fever, dyspnea, fatigue, myalgia and dark urine (brown-coloured). The symptoms appeared after viral infection followed by fever. Acute kidney injury (AKI) developed as a complication, and there was a need for treatment with hemodialysis. At the clinical presentation, the patient had plasma creatine kinase (pCK) level of 130.383 U/L and plasma myoglobin level over 5000 µg/L. Genetic testing (molecular analysis) confirmed the diagnosis of inherited rhabdomyolysis, a metabolic disorder of carnitine palmitoyltransferase II deficiency. A previous episode with the same symptoms, the patient had four years ago but did not ask for medical treatment. The patient was discontinued from hemodialysis because of the resolution of acute kidney injury. The patient was discharged from the hospital in good condition, with a recommendation about his future lifestyle in order to prevent similar episodes.

CONCLUSION: Every patient presenting with myalgia, dark urine (brown-coloured), high level of pCK and development of AKI requiring hemodialysis, should be explored for inherited rhabdomyolysis induced by CPT II deficiency.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Sigauke E, Rakheja D, Kitson K, Bennett MJ. Carnitine palmitoyltransferase II deficiency: A clinical, biochemical, and molecular review. Lab Invest. 2000; 383:1543–1554.

Bonnefont JP, Demaugre F, Prip-Buus C, Saudubray JM, Brivet M, Abadi N, Laure Thuillier L. Carnitine Palmitoyltransferase Deficience. Mol Genet Metab. 1999; 68(4):424-40. https://doi.org/10.1006/mgme.1999.2938 PMid:10607472

Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. Eur J Intern Med.2007; 18:90. https://doi.org/10.1016/j.ejim.2006.09.020 PMid:17338959

Vladutiu GD, Quackenbush EJ, Hainline BE, Albers S, Smail DS, Bennett MJ. Lethal neonatal and severe late infantile forms of carnitine palmitoyltransferase II deficiency associated with compound heterozygosity for different protein truncation mutations. J Pediatr. 2002; 141:734–6. https://doi.org/10.1067/mpd.2002.128545 PMid:12410208

Anichini A, Fanin M, Vianey-Saban C, Cassandrini D, Fiorillo C, Bruno C, Angelini C. Genotype-phenotype correlations in a large series of patients with muscle type CPT II deficiency. Neurol Res. 2011; 33(1):24-32. https://doi.org/10.1179/016164110X12767786356390 PMid:20810031

Orngreen MC, Duno M, Ejstrup R, Christensen E, Schwartz M, Sacchetti M, Vissing J. Fuel utilisation in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol. 2005; 57(1):60–6. https://doi.org/10.1002/ana.20320 PMid:15622536

DiMauro S, DiMauro PMM. Muscle carnitine palmityl transferase deficiency and myoglobinuria. Science. 1973; 182: 929-931, https://doi.org/10.1126/science.182.4115.929 PMid:4745596

Valvukis M, Eftimov A, Zafirovska P, Caparovska E, Pocesta B, Kedev S, Dimovski AJ. Rhabdomyolysis and Cardiomyopathy in a 20-Year-Old Patient with CPT II Deficiency. Case Reports genetics. 2014; Article ID 496410.

Deschauer M, Wieser T, Zierz S. Muscle Carnitine Palmitoyltransferase II DeficiencyClinical and Molecular Genetic Features and Diagnostic. Arch Neurol. 2005; 62(1):37-41. https://doi.org/10.1001/archneur.62.1.37 PMid:15642848

Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol. 1990; 27:181. https://doi.org/10.1002/ana.410270214 PMid:2156480

Olpin SE, Murphy E, Kirk RJ, Taylor RW, Quinlivan R. The Investigation & Treatment of Metabolic Myopathies. J Clin Pathol. 2015; 68(6):410-7. https://doi.org/10.1136/jclinpath-2014-202808 PMid:25878327

Lamhonwah AM, Olpin SE, Pollitt RJ, et al. Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy," 2002 American Journal of Medical Genetics. 2002; 111(3):271–284. https://doi.org/10.1002/ajmg.10585 PMid:12210323

Roe Ch, Sweetman L, Roe D, David F, Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002; 110(2):259-269. https://doi.org/10.1172/JCI0215311

Published

2018-04-12

How to Cite

1.
Gjorgjievski N, Dzekova-Vidimliski P, Petronijevic Z, Selim G, Dejanov P, Tozija L, Sikole A. Carnitine Palmitoyltransferase II Deficiency (CPT II) Followed By Rhabdomyolysis and Acute Kidney Injury. Open Access Maced J Med Sci [Internet]. 2018 Apr. 12 [cited 2023 Feb. 4];6(4):666-8. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2018.158

Issue

Section

C- Case Reports

Most read articles by the same author(s)

1 2 > >>